Erika Taylor

Dr. Erika Taylor

Department of Chemistry, Wesleyan University, Middletown, CT, 06459, USA
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2016 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
TCThomas Christian
Thomas Christian
RSReiko Sakaguchi
Reiko Sakaguchi
APAgata P Perlinska
Agata P Perlinska
GLGeorges Lahoud
Georges Lahoud
TITakuhiro Ito
Takuhiro Ito
YHYa-Ming Hou
Ya-Ming Hou

1 March 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LTLi-Min Ting
Li-Min Ting
WSWuxian Shi
Wuxian Shi
ALAndrzej Lewandowicz
Andrzej Lewandowicz
VSVipender Singh
Vipender Singh
AMAgnes Mwakingwe
Agnes Mwakingwe
KKKami Kim
Kami Kim
Plasmodium falciparum is unable to synthesize purine bases and relies upon purine salvage and purine recycling to meet its purine needs. We report that purines formed as products of polyamine synthesis are recycled in a novel pathway in which 5′-methylthioinosine is generated by adenosine deaminase. The action of P. falciparum purine nucleoside phosphorylase is a convergent step of purine salvage, converting both 5′-methylthioinosine and inosine to hypoxanthine. We used accelerator mass spectrometry to verify that 5′-methylthioinosine is an active nucleic acid precursor in P. falciparum. Prior studies have shown that inhibitors of purine salvage enzymes kill malaria, but potent malaria-specific inhibitors of these enzymes have not been described previously. 5′-Methylthio-immucillin-H, a transition state analogue inhibitor that is selective for malarial relative to human purine nucleoside phosphorylase, kills P. falciparum in culture. Immucillins are currently in clinical trials for other indications and may also have application as anti-malarials.

26 January 2006 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
KCKeith Clinch
Keith Clinch
GEGary B. Evans
Gary B. Evans
GFGeorge W. J. Fleet
George W. J. Fleet
RFRichard H. Furneaux
Richard H. Furneaux
SJStephen W. Johnson
Stephen W. Johnson
PTPeter C. Tyler
Peter C. Tyler
(1R)-1-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-L-ribitol [(+)-5] and (3S,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol [(−)-6] are the L-enantiomers of immucillin-H (D-ImmH) and DADMe-immucillin-H (D-DADMe–ImmH), respectively, these D-isomers being high affinity transition state analogue inhibitors of purine nucleoside phosphorylases (PNPases) developed as potential pharmaceuticals against diseases involving irregular activation of T-cells. The C-nucleoside hydrochloride D-ImmH [(−)-5)·HCl], now “Fodosine™” is in phase II clinical trials as an anti-T-cell leukaemia agent, while D-DADMe–ImmH is a second generation inhibitor with extreme binding to the target enzyme and has entered the clinic for phase I testing as an anti-psoriasis drug. Since the enantiomers of some pharmaceuticals have revealed surprising biological activities, the L-nucleoside analogues (+)-5·HCl and (−)-6, respectively, of D-ImmH and D-DADMe–ImmH, were prepared and their PNPase binding properties were studied. For the synthesis of compound (−)-6 suitable enzyme-based routes to the enantiomerically pure starting material (3S,4S)-4-(hydroxymethyl)pyrrolidin-3-ol [(−)-16] and its enantiomer were developed. The L-enantiomers (+)-5·HCl and (−)-6 bind to the PNPases approximately 5- to 600-times less well than do the D-compounds, but nevertheless remain powerful inhibitors with nanomolar dissociation constants.


1 May 2007 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
PTPeter C. Tyler
Peter C. Tyler
ETErika Taylor
Erika Taylor
RFRichard F. G. Fröhlich
Richard F. G. Fröhlich
VSVern L. Schramm
Vern L. Schramm

13 December 2003 in Biochemistry
Verified
Journal Article
Closed access
ETErika Taylor
Erika Taylor
JGJames B. Garrett
James B. Garrett
JTJames B. Thoden
James B. Thoden
HHHazel M. Holden
Hazel M. Holden
IRIvan Rayment
Ivan Rayment
JGJohn A. Gerlt
John A. Gerlt